Positions

Overview

  • Dr. Franco is board certified in Internal Medicine and Infectious Diseases and Assistant Professor of Medicine at the University of Alabama at Birmingham. His interest focuses on interventions to improve access to care and new therapies in Chronic Hepatitis C; clinical management and trials in HCV mono-infection and HIV-HCV co-infection; and the accelerated pathogenesis of HIV-HCV co-infection. Recently, Dr. Franco had coordinated the Hep C Circle of Care award, instrumental in the expansion of the 1917 Viral Hepatitis Clinic. Since then, the 1917 Viral Hepatitits Clinic had developed collaborations with the Liver Center, the Department of Emergency Medicine and Charity Care at UAB, becoming a major point of linkage to Hepatitis C care for a broad referral base in the State of Alabama.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis PopulationKidney International Reports.  6:1788-1798. 2021
    2021 Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/HCV co-infected womenAIDS.  Publish Ahead of Print. 2021
    2021 Pragmatic Experience with Risk-based versus Universal Hepatitis C Screening in Pregnancy: Detection of Infection and Postpartum Linkage to Care 2021
    2020 Hepatitis C among high-risk alabamians: Disease burden and screening effectivenessJournal of Infectious Diseases.  222:S365-S375. 2020
    2020 Predictors of linkage to care for a nontargeted emergency department hepatitis C screening programAmerican Journal of Emergency Medicine.  38:1396-1401. 2020
    2020 High Prevalence of Hepatitis C Infection among Adult Patients at Four Urban Emergency Departments-Birmingham, Oakland, Baltimore, and Boston, 2015-2017MMWR : Morbidity & Mortality Weekly Report.  69:569-574. 2020
    2020 Cervical and oral human papillomavirus infection in women living with human immunodeficiency virus (HIV) and matched HIV-negative controls in BrazilInfectious Agents and Cancer.  15. 2020
    2020 Direct acting antivirals in hepatitis c-infected kidney transplant recipients: Associations with long-term graft failure and patient mortalityPathogens and Immunity.  5:275-290. 2020
    2019 Author Response to Letter to the Editor Regarding “Potential Problems of Using Same Race Category for Native Hawaiians, Pacific Islanders, and Asians”American Journal of Preventive Medicine.  57:290-291. 2019
    2019 Effectiveness of Direct-Acting Antiviral Therapy in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter StudyOpen Forum Infectious Diseases.  6. 2019
    2018 Racial and Geographic Disparities in Hepatocellular Carcinoma OutcomesAmerican Journal of Preventive Medicine.  55:S40-S48. 2018
    2017 Direct-acting antivirals in kidney transplant patients: Successful hepatitis c treatment and short-term reduction in urinary protein/creatinine ratiosPathogens and Immunity.  2:366-375. 2017
    2017 Continuum of care for hepatitis C virus among patients diagnosed in the emergency department settingClinical Infectious Diseases.  64:1540-1546. 2017
    2016 Characterizing failure to establish hepatitis C care of baby boomers diagnosed in the emergency departmentOpen Forum Infectious Diseases.  3. 2016
    2016 Acute disseminated encephalomyelitis presenting as a brainstem encephalitisClinical Neurology and Neurosurgery.  143:76-79. 2016
    2016 Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central AlabamaClinical Infectious Diseases.  62:613-616. 2016
    2015 Impact of poor retention in HIV medical care on hepatitis B vaccinationJournal of the International Association of Providers of AIDS Care.  14:185-190. 2015
    2015 Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency departmentHepatology.  61:776-782. 2015
    2014 National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United StatesClinical Infectious Diseases.  59:755-764. 2014
    2013 When to start antiretroviral therapy: As soon as possibleBMC Medicine.  11. 2013

    Research Overview

  • Public Health and Outcomes Research in hepatitis C and HIV.
  • Investigator On

  • ACTG Protocol Funds  awarded by University of California, Los Angeles
  • AHRQ ECHO National Nursing Home COVID-19 Action Network  awarded by University of New Mexico
  • AIDS Clinical Trials Group: Protocol Funds FTE Funding  awarded by Brigham and Women's Hospital
  • Alabama Clinical Trials Unit (CTU)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Alabama Clinical Trials Unit (CTU)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Alabama Coalition for Testing, Interventions, and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • DETECT-HIV - Discovering Emerging Trends through Enhanced Community Testing for HIV infection  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • DETECT-HIV – Discovering Emerging Trends through Enhanced Community Testing for HIV Infection  awarded by ALABAMA DEPARTMENT OF PUBLIC HEALTH
  • HCV Early Identification and Linkage to Care  awarded by CDC Foundation
  • HVTN 703/HPTN 081 Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • HVTN Protocol Funding (PF)  awarded by Hutchinson (Fred) Cancer Research Center
  • Initiating Medication Assisted Treatment of Opioid Addiction in the Emergency Department: The ED MAT Protocol  awarded by Substance Abuse & Mental Health Services Administration
  • Initiating Medication Assisted Treatment of Opioid Addiction in the Emergency Department: The ED MAT Protocol  awarded by Substance Abuse & Mental Health Services Administration
  • NIAID-Fred Hutch-Janssen Collaboration CTU/Clinical Trial Site Activities for HVTN 117/118  awarded by Hutchinson (Fred) Cancer Research Center
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by VICAL, INC.
  • Private Grant  awarded by BAVARIAN NORDIC A/S
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GENECURE BIOTECHNOLOGIES, LLC
  • Private Grant  awarded by CEPHEID
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY
  • Private Grant  awarded by PROTEUS DIGITAL HEALTH, INC.
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by BAVARIAN NORDIC A/S
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by GlaxoSmithKline
  • VVTEU Protocol Development and Implementation for Task Areas B-C Phase II Vaccine Trial for Influenza (“Flu Pandemic” or “H7”)  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER
  • Vaccine and Treatment Evaluation Units  awarded by VANDERBILT UNIVERSITY MEDICAL CENTER
  • Vaccine and Treatment Evaluation Units - Admin Task  awarded by VANDERBILT UNIVERSITY
  • Education And Training

  • Jackson Memorial Hospital, Internship
  • Jackson Memorial Hospital, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine in Internal Medicine Residency Program, Federal University of Minas Gerais 2003
  • Full Name

  • Ricardo Franco